FindTrial
Sign In

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

A Single Patient Protocol for TNB-383B, a Bispecific Antibody Targeting BCMA in a Subject With Relapsed/Refractory Multiple Myeloma

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04453397
Enrollment
Unknown
Registered
2020-07-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

Interventions

DRUGTNB-383B

TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.

Sponsors

TeneoOne Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adequate bone marrow function * eGFR ≥ 30 mL/min * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * Serum calcium (corrected for albumin) at or below the ULN range

Exclusion criteria

* Candidate for treatment regimens known to provide clinical benefit in MM * Active infection requiring parenteral anti-infective treatment * Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026